Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study
Authors' conclusion
We found no increased risk of spontaneous loss in women with RA, PsA or SpA but a small increase in women with psoriasis or IBD.
Study context
- Population
- Pregnancies to women with Immune Mediated Inflammatory Diseases (IMID) in the Clinical Practice Research Datalink, 1 January 2000 to 31 June 2020matched cohort
- Exposure
- Pregnancies in women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) or inflammatory bowel disease (IBD) vs matched pregnancies in women with no such diagnosis
- Outcome
- Spontaneous pregnancy loss and major congenital malformations
Methodological detailsUK-based, Clinical Practice Research Datalink
- UK-based
- Clinical Practice Research Datalink
Main finding
As reported in the abstract
Spontaneous pregnancy loss
Each group vs women without an IMIDAdjusted hazard ratio (95% CI)
PsAlowest of range
1.01(0.79–1.28)
IBDhighest of range
1.18(1.07–1.30)
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| Major congenital malformationsIBDvs Women without an IMIDBorderline significance based on sensitivity analyses | 1.31 (1.00–1.71) | |
| 0.512Adjusted odds ratio (log scale) |
Major congenital malformations
- No significant increases in the overall risk of major congenital malformations (MCMs), except IBD
Spontaneous loss by DMARD exposure
- No evidence of increased risk in women taking azathioprine, mesalazine and sulfasalazine
Original publication
Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study. Rheumatology (Oxford). Published 7 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →